DUTCH Weight Control in Atrial Fibrillation Study

NCT06184633 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

280

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation
Obesity
Weight Loss

Interventions

DRUG: Semaglutide 3.2 MG/ML
DRUG: Placebo

Sponsor

Rijnstate Hospital